Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

A comparison of various methods of measuring antidepressant medication adherence among children and adolescents with major depressive disorder in a 12-week open trial of fluoxetine.

Nakonezny PA, Hughes CW, Mayes TL, Sternweis-Yang KH, Kennard BD, Byerly MJ, Emslie GJ.

J Child Adolesc Psychopharmacol. 2010 Oct;20(5):431-9. doi: 10.1089/cap.2009.0108.

2.

Pharmacokinetically and clinician-determined adherence to an antidepressant regimen and clinical outcome in the TORDIA trial.

Woldu H, Porta G, Goldstein T, Sakolsky D, Perel J, Emslie G, Mayes T, Clarke G, Ryan ND, Birmaher B, Wagner KD, Asarnow JR, Keller MB, Brent D.

J Am Acad Child Adolesc Psychiatry. 2011 May;50(5):490-8. doi: 10.1016/j.jaac.2011.01.018. Epub 2011 Mar 9.

3.

Symptom improvement and residual symptoms during acute antidepressant treatment in pediatric major depressive disorder.

Tao R, Emslie GJ, Mayes TL, Nakonezny PA, Kennard BD.

J Child Adolesc Psychopharmacol. 2010 Oct;20(5):423-30. doi: 10.1089/cap.2009.0116.

4.

Early prediction of acute antidepressant treatment response and remission in pediatric major depressive disorder.

Tao R, Emslie G, Mayes T, Nakonezny P, Kennard B, Hughes C.

J Am Acad Child Adolesc Psychiatry. 2009 Jan;48(1):71-8. doi: 10.1097/CHI.0b013e318190043e.

5.

Insomnia moderates outcome of serotonin-selective reuptake inhibitor treatment in depressed youth.

Emslie GJ, Kennard BD, Mayes TL, Nakonezny PA, Zhu L, Tao R, Hughes C, Croarkin P.

J Child Adolesc Psychopharmacol. 2012 Feb;22(1):21-8. doi: 10.1089/cap.2011.0096. Epub 2012 Jan 18.

6.

Do children and adolescents have differential response rates in placebo-controlled trials of fluoxetine?

Mayes TL, Tao R, Rintelmann JW, Carmody T, Hughes CW, Kennard BD, Stewart SM, Emslie GJ.

CNS Spectr. 2007 Feb;12(2):147-54.

PMID:
17277715
7.

The antidepressant treatment response index and treatment outcomes in a placebo-controlled trial of fluoxetine.

Hunter AM, Cook IA, Greenwald SD, Tran ML, Miyamoto KN, Leuchter AF.

J Clin Neurophysiol. 2011 Oct;28(5):478-82. doi: 10.1097/WNP.0b013e318230da8a.

8.

Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults.

Cornelius JR, Bukstein OG, Douaihy AB, Clark DB, Chung TA, Daley DC, Wood DS, Brown SJ.

Drug Alcohol Depend. 2010 Nov 1;112(1-2):39-45. doi: 10.1016/j.drugalcdep.2010.05.010. Epub 2010 Jun 23.

9.

A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder.

Atkinson SD, Prakash A, Zhang Q, Pangallo BA, Bangs ME, Emslie GJ, March JS.

J Child Adolesc Psychopharmacol. 2014 May;24(4):180-9. doi: 10.1089/cap.2013.0146. Epub 2014 May 9.

PMID:
24813026
10.

Melancholic features in inpatients with major depressive disorder associate with differential clinical characteristics and treatment outcomes.

Lin CH, Huang CJ, Liu SK.

Psychiatry Res. 2016 Apr 30;238:368-373. doi: 10.1016/j.psychres.2015.11.009. Epub 2015 Nov 23.

PMID:
26899817
11.

Fluoxetine in adolescents with major depression and an alcohol use disorder: an open-label trial.

Cornelius JR, Bukstein OG, Birmaher B, Salloum IM, Lynch K, Pollock NK, Gershon S, Clark D.

Addict Behav. 2001 Sep-Oct;26(5):735-9.

PMID:
11676382
12.

Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.

March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J; Treatment for Adolescents With Depression Study (TADS) Team.

JAMA. 2004 Aug 18;292(7):807-20.

PMID:
15315995
13.

A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder.

Emslie GJ, Prakash A, Zhang Q, Pangallo BA, Bangs ME, March JS.

J Child Adolesc Psychopharmacol. 2014 May;24(4):170-9. doi: 10.1089/cap.2013.0096. Epub 2014 May 9.

14.

A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression.

Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Carmody T, Rintelmann J.

Arch Gen Psychiatry. 1997 Nov;54(11):1031-7.

PMID:
9366660
15.

Fluoxetine once every third day in the treatment of major depressive disorder.

Tural U, Onder E.

Eur Arch Psychiatry Clin Neurosci. 2003 Dec;253(6):307-12.

PMID:
14714120
16.

The role of readiness to change in response to treatment of adolescent depression.

Lewis CC, Simons AD, Silva SG, Rohde P, Small DM, Murakami JL, High RR, March JS.

J Consult Clin Psychol. 2009 Jun;77(3):422-8. doi: 10.1037/a0014154.

17.

A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial.

Goodyer IM, Dubicka B, Wilkinson P, Kelvin R, Roberts C, Byford S, Breen S, Ford C, Barrett B, Leech A, Rothwell J, White L, Harrington R.

Health Technol Assess. 2008 May;12(14):iii-iv, ix-60.

18.

Anxiety as a predictor of treatment outcome in children and adolescents with depression.

Cheung A, Mayes T, Levitt A, Schaffer A, Michalak E, Kiss A, Emslie G.

J Child Adolesc Psychopharmacol. 2010 Jun;20(3):211-6. doi: 10.1089/cap.2010.0006.

19.

A feasibility study of antidepressant drug therapy in depressed elderly patients with chronic obstructive pulmonary disease.

Yohannes AM, Connolly MJ, Baldwin RC.

Int J Geriatr Psychiatry. 2001 May;16(5):451-4.

PMID:
11376459
20.

The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes.

March JS, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J.

Arch Gen Psychiatry. 2007 Oct;64(10):1132-43. Erratum in: Arch Gen Psychiatry. 2008 Jan;65(1):101.

PMID:
17909125

Supplemental Content

Support Center